Entrada Therapeutics price to sales ratio TRDA
Market value divided by revenue over the last twelve months, since 2024.
- Today, Nov 2, 2026
- 42.5×
- 3-year median
- 3.3×
- Against its 3-year history
- 83rd
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 1.3× to 62.9×
- Peer median
- 1.4×
Entrada Therapeutics' price to sales ratio is 42.5× as of Nov 2, 2026.
That is above its 3-year median of 3.3×, higher than on 83% of days in the last 3 years.
Over that time it ranged from 1.3× in Aug 2025 to 62.9× in Aug 2026.
The median for 10 large drugmakers of a similar size is 1.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 42.5× | 6.2× | 62.9× |
| 2025 | 6.5× | 1.3× | 6.9× |
| 2024 | 3.0× | 2.3× | 3.8× |
Against its peers
Companies in Drug Manufacturers - General nearest Entrada Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| TRDAEntrada Therapeutics | 42.5× |
| NATRNatures Sunshine Products | 0.4× |
| CRMDCorMedix | 0.9× |
| ARVNArvinas | 1.6× |
| PBYIPuma Biotechnology | 2.3× |
| LFVNLifevantage | 0.4× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| ZVRAZevra Therapeutics | 4.4× |
| SPROSpero Therapeutics | 1.3× |
| COLLCollegium Pharmaceutical | 1.0× |
| ABUSArbutus Biopharma | 4.4× |
| Peer median | 1.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Entrada Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.